Investment Thesis
Fuse Medical exhibits fundamental deterioration with negative stockholders' equity of -$231.6K, indicating the company is technically insolvent on a book value basis. Despite strong gross margins of 70%, the company is struggling with profitability (0.9% net margin) and revenue contraction (-8.7% YoY), while operating primarily on thin cash flow generation that may not be sustainable.
Strengths
- Strong gross margin of 70% demonstrates pricing power and efficient production in medical supplies
- Positive operating cash flow of $231.7K with free cash flow matching OCF indicates no capital intensity
- Adequate liquid cash position of $253.4K provides near-term operational cushion
Risks
- Negative stockholders' equity of -$231.6K signals technical insolvency and erosion of shareholder value
- Revenue declining 8.7% YoY combined with minimal net margin of 0.9% suggests business model deterioration
- Critical liquidity weakness with quick ratio of 0.31x indicates difficulty meeting short-term obligations beyond cash on hand
- Liabilities exceed assets ($19.5M vs $19.3M), creating balance sheet stress despite current ratio appearing adequate
- Near-zero insider activity (0 Form 4 filings in 90 days) may indicate lack of management confidence
Key Metrics to Watch
- Quarterly revenue trend and year-over-year growth trajectory
- Path to positive stockholders' equity and timeline for balance sheet recovery
- Operating margin expansion and net margin improvement
- Working capital and quick ratio trends to assess liquidity sustainability
Financial Metrics
Revenue
9.0M
Net Income
79.2K
EPS (Diluted)
$0.00
Free Cash Flow
231.7K
Total Assets
19.3M
Cash
253.4K
Profitability Ratios
Gross Margin
70.0%
Operating Margin
2.3%
Net Margin
0.9%
ROE
N/A
ROA
0.4%
FCF Margin
2.6%
Balance Sheet & Liquidity
Current Ratio
1.06x
Quick Ratio
0.31x
Debt/Equity
N/A
Debt/Assets
101.2%
Interest Coverage
1.83x
Long-term Debt
100.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-25T12:12:10.709597 |
Data as of: 2023-06-30 |
Powered by Claude AI